News

Maze Therapeutics has secured an initial investment commitment of $191m, led by Third Rock Ventures and ARCH Venture Partners. GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and

This new treatment includes the same monoclonal antibody as intravenous Herceptin® (trastuzumab) in combination with recombinant human hyaluronidase PH20, an enzyme that helps to deliver trastuzumab under the

The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent

The clinical trial, which enrolled 41 patients with Parkinson’s Disease, was funded by Parkinson’s UK with support from The Cure Parkinson’s Trust and in association with the North

The approval allows Nuformix to initiate the first dosing of NXP001 in an open-label study to compare the bioavailability of NXP001 to Merck’s EMEND  in healthy subjects. Nuformix

The expanded Farxiga and Xigduo XR labels have been approved to treat patients with T2D and moderate renal impairment, which is a chronic kidney disease with an estimated

New investor Seventure Partners, via its microbiome-focused fund Health for Life Capital™, led the financing along with existing investors Longwood Fund, Domain Associates, Heritage Medical Systems and a

Based in Cambridge of Massachusetts, Anthos Therapeutics will develop and commercialize genetically and pharmacologically validated therapies for high-risk cardiovascular patient populations. Anthos chairman and Blackstone Life Sciences head

“As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. We are excited to